From Computers to Clinics: Advances in Designing Polyphosphate Inhibitors as Novel Anti-thrombotics
Thrombosis, the formation of a potentially deadly blood clot, remains one of the leading causes of death and disability worldwide. Once formed, clots can slow or obstruct normal blood flow, leading to damage to surrounding tissue.
Meet a CBR Member: Mr. James (Jim) Humphries
At the Centre for Blood Research (CBR), the holiday season was inaugurated on December 7th, 2018. We all came together around the Christmas tree to enjoy our annual holiday potluck and gift exchange.
Earl Davie Symposium 2018: In Review
At the Centre for Blood Research (CBR), November is associated with the annual Earl W. Davie Symposium. This highly anticipated multidisciplinary symposium was launched 12 years ago by CBR’s founding director Dr. Ross MacGillivray, who was a trainee in Dr. Earl Davie’s laboratory.
GMOs: Scientific or Social Uncertainty?
Genetic engineering is the process of altering the blueprints of an organism in order to effect some desired change. Since its discovery in the 1970s, this technology has been used to advance research, industry, medicine, and agriculture.
CBR Magazine November 2018
2018 November Magazine for Website by CBR on Scribd
Proteases can be a turn-on, or a turn-off. Or… A Protease-mediated Switch Controls the Transition from Proinflammatory (M1) to Repair (M2) Macrophages
Chronic inflammatory & autoimmune diseases affect many Canadians, and yet the mechanisms behind such conditions are not fully understood and there is no cure available.
Open Access and Open Science: The Call for More Transparency in Science
In May of this year, a group of Swedish universities made the decision not to renew their contracts with publishing giant Elsevier. To researchers who rely on these journals for their day-to-day work this may seem like a drastic move, but this new stand-off is part of a movement toward an open-access model in publishing research.
CBR Summer Students Visit Canadian Blood Services!
What is involved in getting blood that has been donated at a mobile clinic in Campbell River to a patient on the operating table at Vancouver General Hospital?
The Bayer-UBC Bleeding Disorders Collaboratory Continues to Innovate
The Bayer-UBC Bleeding Disorders Collaboratory, established in 2012 with a $750,000 financial commitment from Bayer Inc., has stimulated substantial innovation in the treatment of hemophilia and other bleeding disorders.
The First Targeted Gene Therapy Approved in North America: Luxturna
RPE65-mediated inherited retinal dystrophy leads to severe deterioration of vision and complete blindness in early adulthood. A small subgroup of patients, approximately 1000 people in the United States, have mutations in both paternal and maternal copies of the RPE65 gene that encodes retinoid isomerohydrolase.